Insulin lispro

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023
Public Policy, Government, Pharmaceutical, State, Local, Managed Care, Health, Diabetes, Healthcare Reform, Hospitals, Insulin, Inc., Partnership, Insulin lispro, Patient, Risk, Insulin aspart, Pharmaceutical industry, Civica, Insulin glargine

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, FDA, Insulin lispro, Insulin, Pharmaceutical industry in Switzerland, Pharmaceutical industry, Civica

Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.
  • To ensure redundancy of supply, Ypsomed will provide injector dosing pens from their two manufacturing facilities in Switzerland and Germany.
  • “As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica.
  • Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.

Insulin Drugs Global Market Report 2023

Retrieved on: 
Monday, February 20, 2023
Pharmacy, Diabetes, Type, Safety, Eli Lilly and Company, Acquisition, Cell, JAMA, Research report, Insulin, Overweight, Novo Nordisk, Insulin (medication), Lilly, Prediabetes, Insulin glargine/lixisenatide, Gestational diabetes, Pancreas, Growth, Prevalence, Organization, Investment, Obesity, Patient, Insulin degludec/insulin aspart, Geography, Research, Gene, COVID-19, Uncertainty, Woman, Type 1 diabetes, World Health Organization, Drug development, CRISPR, WHO, Insulin detemir, DSM-IV codes, Pharmaceutical industry, Medical device, Dietary supplement, Insulin lispro, Insulin glargine

The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.

Key Points: 
  • The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.
  • The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The insulin drugs market research report is one of a series of new reports that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry.
  • This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Insurance, Pharmaceutical, Health, Diabetes, Medical Devices, Professional Services, Health Insurance, Insulin, Medicare, Biomedicine, Bigfoot Biomedical, FDA, Bigfoot, Population, NYSE, Medicaid, Insulin aspart, CEO, Walmart, Novo Nordisk, CGM, Diabetes, NVO, Technology, Club, Insurance, American Diabetes Association, Pharmaceutical industry, Facebook, Lilly, Insulin lispro

It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.

Key Points: 
  • It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with insulin-requiring diabetes and will give Bigfoot Unity users greater flexibility to switch between insulin brands when they have a change in insurance.
  • This news marks an important moment in time for Bigfoot as we strive to make insulin diabetes management tools more accessible for people who need them.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

The Senior Citizens League Says, "You Better Check Your Medicare Drug Plan"

Retrieved on: 
Monday, October 31, 2022
Insurance, Social Security, Policy, Insulin glargine/lixisenatide, Social, Diabetes, Thought, Insulin, Friends, Association, Formulary, Medicare Advantage, Johnson, Medicare Part D, Retired Enlisted Association, Prescription, SHIP, Insulin lispro, Elijah Cummings Lower Drug Costs Now Act, Ageing, Blood pressure, Folate, CVS, Walgreens, Wind, Health insurance, Pharmaceutical industry, Citizenship, Insulin glargine, Walmart, Medicare

WASHINGTON, Oct. 26, 2022 /PRNewswire-PRWeb/ -- The recently enacted Inflation Reduction Act requires Medicare Part D plans to cap insulin costs at $35 per month per covered prescription starting in 2023, but to get the savings, diabetic Medicare beneficiaries first need to confirm that their insulin will be covered by their plan next year, warns the Senior Citizens League (TSCL). "If your insulin isn't covered by your plan, the $35 cap will not apply and you could wind up with thousands of dollars in pharmacy bills," says Mary Johnson, a Medicare, and Social Security policy analyst for The Senior Citizen League.

Key Points: 
  • For the past 17 years, Johnson has been helping friends and family check and compare their Medicare coverage options during the annual Medicare Open Enrollment Period.
  • Johnson, who has experience doing drug plan searches, immediately hit a dead end on her first search attempt using the Medicare Drug Plan Finder .
  • "The drug input in the Medicare Drug Plan Finder automatically defaults to the generic name of the drug unless the user overrides it and clicks on 'brand.'
  • With 1.2 million supporters, The Senior Citizens League is one of the nation's largest nonpartisan seniors' groups.

PharmaGiant.com's Online Pharmacy Saves Americans up to 90% on Medication

Retrieved on: 
Thursday, August 11, 2022
Giant, Family, Elijah Cummings Lower Drug Costs Now Act, Insulin, Patient, Generic drug, Pharmaceutical industry, Insulin lispro

Millions of Americans fall into a drug coverage gap each year known as the "donut hole".

Key Points: 
  • Millions of Americans fall into a drug coverage gap each year known as the "donut hole".
  • This means their healthcare plan will stop covering drug costs which results in having to pay full-price for necessary medications.
  • Pharma Giant is ideal for those who find themselves in this scenario, where getting access to affordable drugs is of crucial.
  • With a prescription, Americans can easily & securely order prescription medication online through Pharma Giant ( www.pharmagiant.com ) or by calling toll-free at 1-888-513-2294.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

Retrieved on: 
Wednesday, August 3, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, Pharmacy, Blue Cross, Drug, Prednisone, Health, Blue Shield, Face, PBM, Tablet, Partnership, Patient, Insulin lispro, Insurance, Blue Cross Blue Shield Association, Intermountain Healthcare, Prostate cancer, Sale, Welfare, Insulin aspart, Health Care Service Corporation, CEO, Medication, BCBS, Civica, FDA, Medicare, Prescription, Insulin, Medicare Part D, Dietary supplement, Health insurance, Pharmaceutical industry, Insulin glargine

Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.

Key Points: 
  • Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.
  • Abiraterone was chosen by CivicaScriptmembers as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
  • This is a proud day for CivicaScript as we advance our mission to make generic medicines affordable and available to everyone, said CivicaScript President Gina Guinasso.
  • CivicaScript then works with like-minded payors, PBMs and pharmacies across the country who pass along the cost savings to their customers.

Regulatory Affairs Outsourcing Market Report 2022: Increasing Use of Digital Platforms/Solutions in Regulatory Affairs Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 1, 2022
Health, Pharmaceutical, FDA, Patient, European Medicines Agency, Pressure, Cros, Chief executive officer, Legislation, Regulatory affairs, Industry Standard, Marketing, COVID-19, Growth, MHRA, Health Sciences Authority, Compliance, EMA, Food, Technology, Degenerative disease, Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, US Foods, Government, RA, Rituximab, Medicines and Healthcare products Regulatory Agency, Pfizer, Fine chemical, Pharmaceutical industry, Risk management, Etanercept, Insulin lispro, Trastuzumab, Amgen

The "Regulatory Affairs Outsourcing Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Affairs Outsourcing Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The following factors will drive the global regulatory affairs outsourcing market growth during the forecast period:
    Regulatory affairs service providers offer comprehensive services to companies, from strategic regulatory advice to regulatory maintenance and lifecycle support.
  • The healthcare regulatory affairs outsourcing market is highly competitive and competes with traditional CROs and in-house regulatory affairs departments in pharma/biotech and medical device companies.
  • Thus, the pharmaceutical and medical devices companies are increasingly outsourcing the regulatory affairs activities to CROs.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Retrieved on: 
Friday, June 24, 2022
COVID-19, Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Process, Research, Immortalised cell line, STAR, COVID-19, Delta, Company, Longevity, Volunteering, Serum, Seroconversion, ANVISA, Vaccine, EUA, Stelis, Efficiency, WHO, RNA transfection, Fahrenheit, BSE, Population, Immunization, UK, Omicron, GMP, PD, National Stock Exchange of India, Merck, USFDA, Martek Biosciences Corporation, Insulin glargine, Insulin, Global, Diabetes, CEO, DPH, Peptide, Insulin lispro, Immunoglobulin G, Insulin aspart, Partnership, Technology, Temperature, Merck & Co., Leadership, Stride, SmartCell Technology, National Stock Exchange, Porantha Veeda Puguntha Veeda, CDMO, COVID-19 vaccine, Maintenance, Developing country, Safety, Immunity, Pharmaceutical industry, Fine chemical, Phase

The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).

Key Points: 
  • The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).
  • Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-CTM.
  • The vaccine is a reliable, accessible alternative in these regions, allowing immunization and longevity of immunity with the boosters against the Covid variants of concern.
  • Biolexis Private Limited (Biolexis) is an emerging biotech and vaccine company capable of developing and commercializing products for the Global markets.

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Retrieved on: 
Thursday, June 9, 2022
People, Randomized controlled trial, IO, AID, T1D, Parent, Adult, Time, IDE, Bionics, Human, ADA, LinkedIn, Ageing, Income, Glucagon, Ilet, Standard of care, CGM, Meal, YouTube, American Diabetes Association, Sale, Hypoglycemia, National, GLOBE, Disease, Pancreas, Insulin, Diabetes, Technology, Quality of life, Diagnosis, Twitter, FNP, Population, Insulin lispro, Medical Affairs Bureau, Boston University, Federal, RN, Instagram, Fear, Interim, Education, White, Safety, Pharmaceutical industry, Medical device, Glycated hemoglobin, CONCORD

CONCORD, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) were presented during a session hosted by Dr. Roy W. Beck and clinical investigators at the American Diabetes Association (ADA) 82nd Scientific Sessions. The trial met key endpoints, including consistently showing reduced mean HbA1c across populations regardless of race, education, or income level in exploratory analyses of subpopulations. Dr. Gregory Forlenza explained the study design, remarking that the iLet Bionic Pancreas helped to “remove numeracy” from the management of type 1 diabetes.

Key Points: 
  • Adult users in the bionic pancreas group experienced reductions in diabetes distress and fear of hypoglycemia with statistically significant differences favoring the bionic pancreas group relative to the standard of care group.
  • The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) were presented during a session hosted by Dr. Roy W. Beck and clinical investigators at the American Diabetes Association (ADA) 82nd Scientific Sessions.
  • The trial met key endpoints, including consistently showing reduced mean HbA1c across populations regardless of race, education, or income level in exploratory analyses of subpopulations.
  • Dr. Gregory Forlenza explained the study design, remarking that the iLet Bionic Pancreas helped to remove numeracy from the management of type 1 diabetes.